Abstract: In examples, a method for manufacturing a package comprises coupling first and second semiconductor dies to a first surface of a conductive terminal; applying a dry film to a second surface of the conductive terminal opposite the first surface; removing a portion of the dry film contacting the second surface to form a dry film opening, the dry film opening having a linear, non-curved edge extending along a width of the conductive terminal; etching the second surface through the dry film opening; removing the dry film; plating the second surface; and sawing through the conductive terminal to form the package.

Abstract: A semiconductor package includes a semiconductor component and a plurality of leads electrically connected to the semiconductor component. Each of the leads has a first surface, and has a second surface opposite from the first surface, with a solderable metal on the first surface and the second surface. The solderable metal has a first average thickness on the first surfaces, and has a second average thickness on the second surfaces. The second average thickness is 10 percent to 80 percent of the first average thickness. The semiconductor package is formed by concurrently electroplating the solderable metal on the first surfaces and on the second surfaces. The solderable metal is electroplated on the first surfaces with a first average current, and is electroplated on the second surfaces with a second average current. The second average current is 10 percent to 80 percent of the first average current.

Abstract: The present invention relates to the field of biomedicine, and relates to a pharmaceutical use of a hypoxia-inducible lipid droplet-associated protein or a truncated fragment thereof. Specifically, the present invention relates to a use of a hypoxia-inducible lipid droplet-associated protein or a truncated active fragment thereof in the preparation of a drug for treating or preventing hyperlipidemia, hyperlipidemia complications or neurodegenerative diseases, or a use of the hypoxia-inducible lipid droplet-associated protein or the truncated active fragment thereof in the preparation of a drug for reducing the apolipoprotein level, low-density lipoprotein level, or very low-density lipoprotein level in blood or cerebrospinal fluid.